{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106536","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.588716+00:00","generated_at":"2026-05-17T15:30:56.445542+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Quince completes Phase 3 NEAT enrollment; Q2 net loss $16.1M","bullets":["Pivotal Phase 3 NEAT trial enrollment completed with 105 participants; topline results expected Q1 2026.","Cash $34.7M; private placement raised ~$11.5M upfront at >10% premium, potential $10.4M from warrants.","Q2 net loss $16.1M ($0.34/shr); R&D $6.6M, G&A $3.3M; cash runway into Q2 2026.","Strategic relationship with Option Care Health (OPCH) to support U.S. commercial launch of eDSP.","New SAB member Dr. Hassan Abolhassani appointed; Phase 2 DMD study design finalized."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106536","json":"https://secwatch.observer/filing/0000950170-25-106536.json","markdown":"https://secwatch.observer/filing/0000950170-25-106536.md","text":"https://secwatch.observer/filing/0000950170-25-106536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000095017025106536/0000950170-25-106536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000095017025106536/qncx-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:30:56.445542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}